Literature DB >> 30504373

Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells.

Michele Massimino1,2, Elena Tirrò3,2, Stefania Stella3,2, Francesco Frasca4, Veronica Vella5, Laura Sciacca6, Maria Stella Pennisi3,2, Silvia Rita Vitale3,2, Adriana Puma3,2, Chiara Romano3,2, Livia Manzella3,2.   

Abstract

BACKGROUND: Poorly differentiated (PDTC) and anaplastic thyroid (ATC) cancer cells are characterized by the acquisition of epigenetic abnormalities, leading to the silencing of both the sodium iodide co-transporter and the Coxsackie adenovirus receptor. As aberrant histone acetylation and DNA methylation represent epigenetic mechanisms involved in neoplastic transformation, our study investigated the anticancer properties of epigenetic modifiers in thyroid carcinoma.
MATERIALS AND METHODS: The cytotoxicity and gene expression modulation of histone deacetylase and DNA methyltransferase inhibitors were evaluated in both PDTC and ATC.
RESULTS: Epigenetic treatments were cytotoxic to tumor thyrocytes and restored sodium iodide co-transporter and Coxsackie adenovirus receptor, expression as well as radioiodine uptake, in PDTC but not in ATC. However, ectopic expression sodium iodide co-transporter re-activated radioiodine incorporation in ATC.
CONCLUSION: The ability of epigenetic treatments to interfere with tumor proliferation and induce Coxsackie adenovirus receptor expression, coupled with the ability of ectopic sodium iodide co-transporter to restore radioiodine uptake, raise the possibility that these therapeutic approaches may provide clinical benefit to patients with thyroid carcinoma refractory to radioiodine treatment. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Coxsackie adenovirus receptor; DNA methyltransferase; HDAC; Thyroid; epigenetic treatment; sodium iodide co-transporter

Mesh:

Substances:

Year:  2018        PMID: 30504373     DOI: 10.21873/anticanres.13032

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.

Authors:  Stefania Stella; Silvia Rita Vitale; Michele Massimino; Gianmarco Motta; Claudio Longhitano; Katia Lanzafame; Federica Martorana; Carmine Fazzari; Giada Maria Vecchio; Elena Tirrò; Nicola Inzerilli; Rosaria Carciotto; Livia Manzella; Michele Caruso; Paolo Vigneri
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

2.  Exploration of the Potential Biomarkers of Papillary Thyroid Cancer (PTC) Based on RT2 Profiler PCR Arrays and Bioinformatics Analysis.

Authors:  Ying Peng; Han-Wen Zhang; Wei-Han Cao; Ying Mao; Ruo-Chuan Cheng
Journal:  Cancer Manag Res       Date:  2020-09-28       Impact factor: 3.989

Review 3.  Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.

Authors:  Ji Min Oh; Byeong-Cheol Ahn
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

Review 4.  Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma.

Authors:  Elena Tirrò; Michele Massimino; Chiara Romano; Federica Martorana; Maria Stella Pennisi; Stefania Stella; Giuliana Pavone; Sandra Di Gregorio; Adriana Puma; Cristina Tomarchio; Silvia Rita Vitale; Livia Manzella; Paolo Vigneri
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

5.  Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells.

Authors:  Michele Massimino; Paolo Vigneri; Stefania Stella; Elena Tirrò; Maria Stella Pennisi; Laura Nunziatina Parrinello; Calogero Vetro; Livia Manzella; Fabio Stagno; Francesco Di Raimondo
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

6.  Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.

Authors:  Livia Manzella; Elena Tirrò; Silvia Rita Vitale; Adriana Puma; Maria Letizia Consoli; Loredana Tambè; Maria Stella Pennisi; Sandra DI Gregorio; Chiara Romano; Cristina Tomarchio; Francesco DI Raimondo; Fabio Stagno
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 7.  Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.

Authors:  X Cai; R Wang; J Tan; Z Meng; N Li
Journal:  Clin Transl Oncol       Date:  2021-06-08       Impact factor: 3.405

Review 8.  Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.

Authors:  Elena Tirrò; Federica Martorana; Chiara Romano; Silvia Rita Vitale; Gianmarco Motta; Sandra Di Gregorio; Michele Massimino; Maria Stella Pennisi; Stefania Stella; Adriana Puma; Fiorenza Gianì; Marco Russo; Livia Manzella; Paolo Vigneri
Journal:  Genes (Basel)       Date:  2019-09-13       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.